206 related articles for article (PubMed ID: 20444731)
1. Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma.
Abdul-Al HM; Wang G; Makhlouf HR; Goodman ZD
Int J Surg Pathol; 2010 Oct; 18(5):313-8. PubMed ID: 20444731
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers.
Witjes CD; ten Kate FJ; Verhoef C; de Man RA; IJzermans JN
J Clin Pathol; 2013 Aug; 66(8):687-91. PubMed ID: 23585667
[TBL] [Abstract][Full Text] [Related]
3. Carcinoma, a fibrolamellar variant--immunohistochemical analysis of 4 cases.
Górnicka B; Ziarkiewicz-Wróblewska B; Wróblewski T; Wilczynski GM; Koperski L; Krawczyk M; Wasiutynski A
Hepatogastroenterology; 2005; 52(62):519-23. PubMed ID: 15816470
[TBL] [Abstract][Full Text] [Related]
4. Primary liver carcinoma arising in people younger than 30 years.
Klein WM; Molmenti EP; Colombani PM; Grover DS; Schwarz KB; Boitnott J; Torbenson MS
Am J Clin Pathol; 2005 Oct; 124(4):512-8. PubMed ID: 16146811
[TBL] [Abstract][Full Text] [Related]
5. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z
Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053
[TBL] [Abstract][Full Text] [Related]
6. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
8. [A particular hepatocellular carcinoma combining the ordinary and the fibrolamellar variant].
Zermani R; Charfi L; Kourda N; Farah F; Rammeh S; Trabelsi O; Zaouch A; Ben Jilani S
Tunis Med; 2005 Jul; 83(7):419-21. PubMed ID: 16220700
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
Stroescu C; Herlea V; Dragnea A; Popescu I
J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
Kandil DH; Cooper K
Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
[TBL] [Abstract][Full Text] [Related]
11. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.
Maeda T; Kajiyama K; Adachi E; Takenaka K; Sugimachi K; Tsuneyoshi M
Mod Pathol; 1996 Sep; 9(9):901-9. PubMed ID: 8878022
[TBL] [Abstract][Full Text] [Related]
12. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.
Baumhoer D; Tornillo L; Stadlmann S; Roncalli M; Diamantis EK; Terracciano LM
Am J Clin Pathol; 2008 Jun; 129(6):899-906. PubMed ID: 18480006
[TBL] [Abstract][Full Text] [Related]
13. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
14. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
15. The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma.
Karabork A; Kaygusuz G; Ekinci C
Pathol Res Pract; 2010 Aug; 206(8):572-7. PubMed ID: 20400233
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH
Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925
[TBL] [Abstract][Full Text] [Related]
18. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies.
Fujiwara M; Kwok S; Yano H; Pai RK
Cancer Cytopathol; 2012 Aug; 120(4):230-7. PubMed ID: 22434791
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
[TBL] [Abstract][Full Text] [Related]
20. Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma.
Aishima S; Nishihara Y; Kuroda Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M
Am J Surg Pathol; 2007 May; 31(5):783-91. PubMed ID: 17460464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
